- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HCW Biologics Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
| Di | HCW Biologics Inc.: HCW Biologics' TGF-ß Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells | 1 | GlobeNewswire (USA) | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 20.08. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | 362 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| 14.08. | HCW Biologics Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | 563 | GlobeNewswire (Europe) | MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion... ► Artikel lesen | |
| 30.06. | HCW Biologics regains Nasdaq compliance, plans stock split | 1 | Investing.com | ||
| 30.06. | HCW Biologics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 30.06. | HCW Biologics Inc.: HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter | 182 | GlobeNewswire (Europe) | MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative... ► Artikel lesen | |
| 26.06. | HCW Biologics Commences 1-for-6 Reverse Stock Split | 1 | RTTNews | ||
| 26.06. | HCW Biologics executes 1-for-6 reverse stock split for Nasdaq | 2 | Investing.com | ||
| 26.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.06. | HCW Biologics Inc.: HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 | 363 | GlobeNewswire (Europe) | Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements... ► Artikel lesen | |
| 18.06. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 16.06. | Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss | 1 | Benzinga.com | ||
| 16.06. | HCW Biologics Inc.: HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata | 273 | GlobeNewswire (Europe) | Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants... ► Artikel lesen | |
| 15.06. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,36 | -3,30 % | Could Arrowhead Pharmaceuticals (ARWR)'s Plozasiran Become the Catalyst for a Major Stock Re-rating? | ||
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 13,485 | -2,56 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| REVOLUTION MEDICINES | 180,25 | +0,42 % | Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It | ||
| MOLECULIN BIOTECH | 0,640 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,29 % bei einem Aktienkurs von 3,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.